Predict your next investment

Angel Investor (Group)
HEALTHCARE | Drug Development
galeratx.com

See what CB Insights has to offer

Stage

IPO | IPO

Total Raised

$142.94M

Date of IPO

11/7/2019

Market Cap

0.03B

Stock Price

1.27

About Galera Therapeutics

Galera Therapeutics (NASDAQ: GRTX) develops drugs targeting oxygen metabolic pathways. The Company's lead compounds are highly selective small molecule dismutase mimetics that closely mimic the activity of the human superoxide dismutase enzymes. While the biology of the superoxide dismutase family suggests a broad range of potential applications, Galera is focusing its development on the prevention of radiation-induced toxicity, including mucositis, and the treatment of cancer.

Galera Therapeutics Headquarter Location

2 West Liberty Boulevard Suite 110

Malvern, Pennsylvania, 19355,

United States

610-725-1500

Latest Galera Therapeutics News

Galera to Present at Two Upcoming Investor Conferences in November

Nov 15, 2021

On-demand beginning at 10 a.m. ET Webcasts from the two presentations will be accessible from the Investors page of Galera’s website, investors.galeratx.com . Following the event, archived webcasts will be available on the Galera website for 30 days. About Galera Therapeutics Galera Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera’s technology consists of selective small molecule dismutase mimetics that are in late-stage development in patients with cancer. Avasopasem manganese (GC4419, also referred to as avasopasem) is in development for radiotherapy-induced toxicities, including SOM in patients with head and neck cancer and esophagitis in patients with lung cancer. Avasopasem has been granted FDA Fast Track and Breakthrough Therapy designations for the reduction of SOM induced by radiotherapy, with or without systemic therapy. Galera’s second dismutase mimetic product candidate, rucosopasem manganese (GC4711, also referred to as rucosopasem), is in clinical-stage development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information, please visit  www.galeratx.com . Investor Contacts:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Galera Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Galera Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Galera Therapeutics Patents

Galera Therapeutics has filed 5 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/27/2013

10/6/2015

Antioxidants, Free radicals, Animal testing, Animal rights, Oxidoreductases

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/27/2013

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

10/6/2015

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Antioxidants, Free radicals, Animal testing, Animal rights, Oxidoreductases

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Galera Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Galera Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.